Now that the phase 1 trials are starting to prove SBP002 as an...

Now that the phase 1 trials are starting to prove SBP002 as an effective anti-cancer agent , it is worth having another look at some of positive results that came from the special access program .
patients "under the SAS are usually in very late stage disease with significant non-responsive tumor mass. On an average the patients are in the last few months of life. The chance of success is low and the prognosis is bleak. Solbec have had some promising results with reports from treating physicians reporting tumor size reduction, reduction in tumor growth rates, extension of life as well as many other positive effects (see above).

SBP002 has been taken orally using enteric-coated tablets and has shown promising results in secondary endometrial cancer to the lung. After 3 months treatment all but two of the patients TUMORS HAD DISAPPEARED (multiple nodules present before treatment) patient had been given approximately three months to live by oncologist and is still alive 18 months later. A male with late stage pancreatic cancer went into LONG TERM REMISSION after taking the tablets. A patient with metastatic melanoma was shown to have TOTAL REMISSION of small lung tumors whilst on oral therapy.

A male with metastatic melanoma to the lung had aggressive disease with four tumors in Feb 2001 and 7 in mar 2001. The disease was non-responsive to standard chemotherapy. He inhaled SBP002 50mg per day for 14 days and had NO FURTHER TUMOR GROWTH.

Direct injection into large Basal cell and Squamous cell cancers on the face have shown very aggressive anti tumor activity. Figures 5 and 6 show facial tumors treated with intertumoral SBP002. Direct injection into a large lymphatic cancer of the neck resulted in ERADICATION OF THE TUMOUR.

There have been a significant number of similar cases with very good response. It is difficult to attribute the result to a particular treatment with SAS patients as they are often on more that one therapy. The circumstantial evidence for SBP002 is still convincing."
Looking forward to the final Phase 1 results .
Cheers .